UBS Upgrades Luminex to Buy | GenomeWeb

NEW YORK (GenomeWeb News) – UBS today upgraded Luminex to a Buy rating, noting uptake of the company's gastrointestinal panel, the Eragen acquisition, and a favorable profile amid macro challenges.

The investment bank upgraded the Austin, Texas-based company from a prior Neutral rating and lowered the 12-month price target on its stock to $22 from $25.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.